Altimmune, Inc. (NASDAQ:ALT) Stock Has Consensus Price Target of $14.33 According to Brokerages

Shares of Altimmune, Inc. (NASDAQ:ALT) have been given an average rating of “Moderate Buy” by the ten analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $14.33.

A number of analysts have issued reports on ALT shares. Evercore reiterated an “outperform” rating on shares of Altimmune in a research note on Wednesday, September 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a report on Monday, September 21st. Finally, HC Wainwright restated a “buy” rating on shares of Altimmune in a report on Tuesday, July 28th.

Hedge Funds Weigh In On Altimmune

Several hedge funds have recently bought and sold shares of ALT. Dimensional Fund Advisors LP boosted its stake in shares of Altimmune by 268.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,045,926 shares of the company’s stock worth $3,221,000 after acquiring an additional 762,223 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of Altimmune by 48.6% during the 1st quarter. Bank of America Corp DE now owns 570,203 shares of the company’s stock valued at $1,756,000 after acquiring an additional 186,420 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Altimmune during the 2nd quarter valued at about $2,097,000. Squarepoint Ops LLC increased its holdings in shares of Altimmune by 1,016.5% during the 2nd quarter. Squarepoint Ops LLC now owns 202,380 shares of the company’s stock valued at $615,000 after acquiring an additional 184,254 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. raised its stake in shares of Altimmune by 156.5% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 518,198 shares of the company’s stock valued at $1,575,000 after acquiring an additional 316,209 shares in the last quarter. 78.05% of the stock is owned by institutional investors and hedge funds.

Altimmune Stock Performance

Shares of NASDAQ ALT opened at $2.05 on Tuesday. The business’s 50-day moving average price is $2.90 and its two-hundred day moving average price is $3.33. The company has a debt-to-equity ratio of 0.07, a current ratio of 26.78 and a quick ratio of 26.78. Altimmune has a one year low of $2.02 and a one year high of $6.44. The company has a market capitalization of $398.77 million, a P/E ratio of -2.63 and a beta of 0.06.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.02. Analysts anticipate that Altimmune will post -0.58 earnings per share for the current fiscal year.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for obesity and liver diseases. The company’s research programs are designed to address metabolic and inflammatory conditions with significant unmet medical needs.

Altimmune’s lead product candidate is pemvidutide, an investigational dual GLP-1 and glucagon receptor agonist being evaluated for chronic weight management and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease.